结核与肺部疾病杂志 ›› 2025, Vol. 6 ›› Issue (4): 436-443.doi: 10.19983/j.issn.2096-8493.20250060

• 论著 • 上一篇    下一篇

不同剂量艾司氯胺酮对胸腔镜手术肺结核患者围术期肺功能及术后肺部并发症的影响

刘彩芳1, 宗华2(), 高云飞2, 严瑾3   

  1. 1新疆医科大学第八临床医学院,乌鲁木齐 830000
    2新疆维吾尔自治区第六人民医院手术麻醉科,乌鲁木齐 830000
    3新疆维吾尔自治区第六人民医院教学科研管理办公室,乌鲁木齐 830000
  • 收稿日期:2025-04-04 出版日期:2025-08-20 发布日期:2025-08-08
  • 通信作者: 宗华,Email:2441287875@qq.com
  • 基金资助:
    新疆维吾尔自治区自然科学基金面上项目(2021D01A162)

The effect of different doses of esketamine on perioperative lung function and postoperative pulmonary complications in patients with pulmonary tuberculosis undergoing thoracoscopic surgery

Liu Caifang1, Zong Hua2(), Gao Yunfei2, Yan Jin3   

  1. 1The Eighth Clinical Medical College,Xinjiang Medical University, Urumqi 830000, China
    2Department of Surgical Anaesthesiology,The Sixth People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China
    3Teaching and Research Management Office,The Sixth People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China
  • Received:2025-04-04 Online:2025-08-20 Published:2025-08-08
  • Contact: Zong Hua,Email:2441287875@qq.com
  • Supported by:
    Xinjiang Uygur Automous Region Natural Science Foundation General Project(2021D01A162)

摘要:

目的: 探讨不同剂量艾司氯胺酮对胸腔镜手术肺结核患者围术期肺功能及术后肺部并发症的影响。方法: 前瞻性纳入新疆维吾尔自治区第六人民医院2023年9月至2024年9月择期行胸腔镜手术的肺结核患者90例,随机分为三组:低剂量组(术中持续输注艾司氯胺酮0.125mg·kg-1·h-1)、高剂量组(术中持续输注艾司氯胺酮0.25mg·kg-1· h-1)和对照组(术中持续输注等体积生理盐水),每组各30例。计算每组患者双肺通气后5min(T1)、单肺通气后15min(T2)、单肺通气后90min(T3)的氧合指数、肺泡动脉氧分压差、肺动态顺应性。采用酶联免疫吸附法测定术前1d及术后1d、3d的白细胞介素-6(IL-6)、血清葡萄糖浓度。记录手术/麻醉时间、拔管时间、术后住院时间等时效指标,同步记录血管活性药物使用情况。记录术后3d内不良反应及术后7d内肺部并发症发生情况。结果: (1)低剂量组、高剂量组和对照组在T2、T3时间点的氧合指数[分别为(245.8±26.5)mmHg、(258.2±25.2)mmHg和(229.1±30.9)mmHg;(239.9±28.0)mmHg、(241.3±32.7)mmHg和(223.5±23.5)mmHg]、肺泡动脉氧分压差[分别为(140.5±29.3)mmHg、(137.6±25.6)mmHg和(163.4±32.9)mmHg;(139.7±28.0)mmHg、(131.8±35.3)mmHg和(162.9±25.1)mmHg],差异均有统计学意义(F值分别为10.818、3.665、6.924、8.841,P值均<0.05)。(2)低剂量组、高剂量组和对照组在术后1d、术后3d的IL-6[分别为(158.77±23.50)ng/L、(154.71±28.90)ng/L和(173.16±26.13)ng/L;(44.99±16.32)ng/L、(42.85±21.46)ng/L和(78.40±22.61)ng/L],差异均有统计学意义(F值分别为4.086、28.891,P值均<0.05)。低剂量组、高剂量组和对照组在术后3d的GLU浓度[分别为(5.40±0.63)mmol/L、(4.86±0.48)mmol/L和(6.18±2.08)mmol/L],差异有统计学意义(F=8.001,P<0.05)。(3)三组患者术后3d内的不良反应均为恶心呕吐,低剂量组、高剂量组和对照组发生率分别为33.3%(10/30)、36.7%(11/30)和70.0%(21/30),差异有统计学意义(χ2=5.424,P<0.05)。低剂量组、高剂量组和对照组术后7d肺部并发症的发生率分别为33.3%(10/30)、26.7%(8/30)、36.7%(11/30),差异无统计学意义(χ2=0.712,P>0.05),但与对照组相比,高剂量组胸腔积液的发生率较低[低剂量组、高剂量组和对照组分别为13.3%(4/30)、3.3%(1/30)、26.7%(8/30),χ2=6.653,P<0.05]。结论: 在胸腔镜手术中,持续输注艾司氯胺酮可改善肺结核患者术中氧合情况,降低术后应激反应,保护肺功能,加快术后恢复。

关键词: 艾司氯胺酮, 胸外科手术,电视辅助, 结核,肺, 呼吸功能试验

Abstract:

Objective: To investigate the effects of different doses of esketamine on perioperative lung function and postoperative pulmonary complications in patients with pulmonary tuberculosis undergoing thoracoscopic surgery. Methods: A prospective study was conducted at the Sixth People’s Hospital of the Xinjiang Uygur Autonomous Region from September 2023 to September 2024, enrolling 90 patients with pulmonary tuberculosis who underwent elective thoracoscopic surgery. The patients were randomly divided into three groups: the low-dose group (continuous intraoperative infusion of esketamine at 0.125 mg·kg-1· h-1), the high-dose group (continuous intraoperative infusion of esketamine at 0.25 mg·kg-1· h-1), and the control group (continuous intraoperative infusion of an equal volume of normal saline), with 30 patients in each group,then calculated their oxygenation index, alveolar-arterial oxygen pressure difference, and pulmonary dynamic compliance at 5 minutes after bilateral lung ventilation (T1), 15 minutes after unilateral lung ventilation (T2), and 90 minutes after unilateral lung ventilation (T3) for each group of patients, examined their interleukin 6 and serum glucose concentrations using enzyme-linked immunosorbent assay one day before surgery and on the first and third day after surgery. Time-sensitive indicators such as surgery/anaesthesia time, tube removal time, and postoperative hospitalisation time were recorded, and the usage of vasoactive drugs were simultaneously recorded, also for adverse reactions within 3 postoperative days and pulmonary complications within 7 postoperative days. Results: (1) The average oxygenation index at time points T2 and T3 for the low-dose group, high-dose group, and control group were ((245.8±26.5) mmHg, (258.2±25.2) mmHg, and (229.1±30.9) mmHg;(239.9±28.0) mmHg, (241.3±32.7) mmHg and (223.5±23.5) mmHg), and the average alveolar-arterial oxygen pressure difference were ((140.5±29.3) mmHg, (137.6±25.6) mmHg and (163.4±32.9) mmHg; (139.7±28.0) mmHg, (131.8±35.3) mmHg and (162.9±25.1) mmHg), with statistically significant differences (F values were 10.818, 3.665, 6.924, and 8.841, and P values all <0.05). (2) The average IL-6 levels in the low-dose group, high-dose group, and control group at post-operative Day1 and Day3 were ((158.77±23.50) ng/L, (154.71±28.90) ng/L, and (173.16±26.13) ng/L; (44.99±16.32) ng/L, (42.85±21.46) ng/L, and (78.40±22.61) ng/L), with statistically significant differences (F values of 4.086 and 28.891, respectively, and P values all <0.05).The average GLU concentrations at postoperative Day3 in the low-dose group, high-dose group, and control group were (5.40±0.63) mmol/L, (4.86±0.48) mmol/L, and (6.18±2.08) mmol/L, showed statistically significant differences (F=8.001, P<0.05). (3) Adverse reactions within 3 postoperative days in all three groups were nausea and vomiting. The incidence rates in the low-dose group, high-dose group, and control group were 33.3% (10/30), 36.7% (11/30), and 70.0% (21/30), respectively, with statistically significant differences (χ2=5.424, P<0.05). The incidence rates of pulmonary complications within 7 postoperative days in the 3 groups were 33.3% (10/30), 26.7% (8/30), and 36.7% (11/30), respectively, with no statistically significant difference (χ2=0.712, P>0.05). However, compared with the control group, the incidence of pleural effusion was lower in the high-dose group, the low-dose group, high-dose group, and control group got rates of 13.3% (4/30), 3.3% (1/30), and 26.7% (8/30),respectively (χ2=6.653, P<0.05). Conclusion: In thoracoscopic surgery, continuous infusion of esketamine can improve intraoperative oxygenation of patients with pulmonary tuberculosis, reduce postoperative stress responses, protect lung function, and accelerate postoperative recovery.

Key words: Esketamine, Thoracic surgery,video-assisted, Tuberculosis, pulmonary, Respiratory function tests

中图分类号: